Avalo Therapeutics terminates $50M at-the-market equity offering with Cantor and RBC

Item 1.02 Termination of a Material Definitive Agreement. As previously disclosed in July 2021, Avalo Therapeutics, Inc. (the “Company”), entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) and RBC Capital Markets, LLC (“RBC”, and collectively with Cantor, the “Sales Agents”), as sales agents, pursuant to which the Company may offer and sell, from time to time through the Sales Agents, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0 million. On April 20, 2023, the Company delivered written notice to Cantor and RBC to terminate the Sales Agreement, effective no later than April 30, 2023, pursuant to Section 12(b) of the Sales Agreement. The Company is not subject to any termination penalties related to the termination of the Sales Agreement. The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by referen